Skip to main content

Table 1 General data of patients in the two groups

From: Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients

 

Experimental group (n = 65)

Control group (n = 65)

χ2 vale

P value

Age (years)

40.83 ± 3.21

40.79 ± 3.19

0.071

0.944

Male/female

33/32

34/31

0.031

0.861

BMI (kg/m2)

23.67 ± 0.21

23.66 ± 0.19

0.285

0.776

Course of disease (h)

24.36 ± 2.08

24.21 ± 1.76

0.444

0.658

Degree of disease (n)

    

Mild

19

21

0.144

0.704

Moderate

46

44

  

Range of lesions (n)

    

Left hemi-colon

17

15

0.166

0.684

Pancolitis

48

50

  

Pre-treatment mayo score (points)

    

Mild

7.21 ± 0.63

7.13 ± 0.59

0.415

0.680

Moderate

8.26 ± 2.29

8.58 ± 2.13

− 0.458

0.649

  1. BMI, Body Mass Index